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Abstract: Portal hypertension is a common complication of liver disease, either acute or
chronic. Consequently, in chronic liver disease, such as the hypertensive mesenteric venous
pathology, the coexisting inflammatory response is classically characterized by the splanchnic
blood circulation. However, a vascular lymphatic pathology is produced simultaneously with
the splanchnic arterio-venous impairments. The pathological increase of the mesenteric venous
pressure, by mechanotransduction of the venous endothelium hyperpressure, causes an inflammatory
response involving the subendothelial mast cells and the lymphatic endothelium of the intestinal
villi lacteal. In portal hypertension, the intestinal lymphatic inflammatory response through the
development of mesenteric-systemic lymphatic collateral vessels favors the systemic diffusion of
substances with a molecular pattern associated with damage and pathogens of intestinal origin.
When the chronic hepatic insufficiency worsens the portal hypertensive inflammatory response,
the splanchnic lymphatic system transports the hyperplasied intestinal mast cells to the mesenteric
lymphatic complex. Then, an acquired immune response regulating a new hepato-intestinal metabolic
scenario is activated. Therefore, reduction of the hepatic metabolism would reduce its key centralized
functions, such as the metabolic, detoxifying and antioxidant functions which would try to be
substituted by their peroxisome activity, among other functions of the mast cells.
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1. Portal Hypertension and Splanchnic Lymphatic Pathology
Portal hypertension is defined as the pathological increase of portal pressure, which is determined
by a hepatic venous pressure gradient (HVPG) greater than 5 mmHg, with complications arising once
this pressure exceeds 10 mmHg. As a result of elevated pressures within the portal vein, several
complications can arise, including the development of esophageal and gastric varices, ascites, hepatic
encephalopathy, as well as complications secondary to circulatory dysfunction, including hepatorenal
syndrome, portopulmonary syndrome, and hepatopulmonary syndrome. In turn, the etiology of
increased portal resistance is commonly categorized according to the anatomical location in terms of
pre-hepatic, intra-hepatic, and post-hepatic causes [1]. Intrahepatic portal hypertension is the most
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frequent in the clinical area and is principally produced by toxic substances (alcoholic liver disease),
chronic infections due to HBV and/or HCV, and metabolic pathologies (Non-alcoholic liver steatosis,
NASH) [2,3].
Pathological portal pressure increases when it is related to liver disease, producing systemic
and splanchnic impairments that together could be considered a syndrome; that is, the portal
hypertensive syndrome.
Until now, the study of portal hypertension has mainly focused on the blood vascular
ethiopathogeny in detriment of the lymphatic vascularization. Consequently, hyperdynamic circulation
and excessive angiogenesis are key blood vascular characteristics of portal hypertension in the
splanchnic area. Excessive angiogenesis is localized in the macrocirculation, with the development
of porto-systemic collateral circulation, with an increase of the mucosa and submucosa blood
vascularization in the gastrointestinal layer. Hence, the enteropathy developed in portal hypertension
has been named portal hypertensive vascular enteropathy [4].
Furthermore, the leading role of the splanchnic venous vascularization in portal hypertension
is easily demonstrable in the experimental models. In particular, in the model of prehepatic portal
hypertension in the rat by partial ligation of the portal vein, it is possible to observe in the short-term
the great splanchnic angiogenic response that is produced. Thus, through a laparotomy performed in
the early evolutive stages, the existence of porto-systemic collateral circulation, of paraoesophageal,
splenorenal and pararectal types, can be observed. This portal hypertensive enteropathy is characterized
by a great dilation and tortuosity of the mesenteric vein branches. Taken all together, these alterations
represent the ability of the splanchnic venous pressure to stimulate the blood vascular endothelium
proliferation [5]. Since the increase of blood pressure in portal hypertension is attributed to the
mechanical energy increase, it is obvious that this type of energy through the mechanism known as the
mechanotransductor, has the ability to induce the abovementioned angiogenic stimulus early. In turn,
it has been shown that excessive endothelial mechanotransduction is a proinflammatory stimulus.
Therefore, it is proposed that the endothelial pathology of portal hypertension is inflammatory [6].
Particularly, the splanchnic post-capillary venule endothelium has great sensibility to the portal
pressure increase, when the hypertension is secondary to a liver disease. This fact allows for an early
change in the endothelium phenotype, which expresses an inflammatory phenotype before developing
hepatic insufficiency [7].
However, portal hypertension also induces the splanchnic lymphatic pathology, although this
alteration has been undervalued until recently because these macroscopic alterations are not as
noticeable as the blood ones. A more detailed study of the splanchnic lymphatic macro- and
microcirculation would allow us to confirm the key role of this lymphatic vascular pathology in
terms of the blood vascular pathology in portal hypertension.
2. The Mast Cell as Mediator of the Splanchnic Lymphatic Pathology in Portal Hypertension
Since the mast cells are located in close proximity to the blood and lymphatic microcirculation,
through a paracrine mechanism, they can influence the endothelial cells of both the blood and
lymphatic circulatory systems. In addition, mast cells can act on other cell residents in this environment,
including pericytes, fibroblasts, and other immune cells, both resident and recruited. [8]. Particularly,
the inflammatory alterations induced by mechanical energy in portal hypertension could be influenced
by endothelial mechanotransduction in the expression of a particular inflammatory phenotype in the
resident mast cells. The functional heterogeneity and plasticity of the mast cells would condition the
heterogeneity of the blood and lymphatic endothelial cells that it influences [9]. This would explain
why the functional endothelial cell-mast cell coupling plays the key role in the splanchnic inflammatory
impairments induced by mechanotransduction in portal hypertension. In experimental and clinical
portal hypertension, an increase of the splanchnic mast cells as well as the changes of their phenotype
have been demonstrated [10–12]. The increase of the mast cells number in the hepato-intestinal axis
when a pathological increase of portal hypertension is produced, suggests that portal hypertension
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is the cause of mastocytosis. In turn, the change of phenotype of these cells, considered immune
cells in portal hypertension, was originally demonstrated in rodents [13]. Two types of mast cells, the
connective tissue mast cells (CTMC), and the mucosal mast cells (MMC) are well defined in these
mammals [14]. These two populations of mast cells differ in many aspects, including their responses to
drugs and secretagogues [15]. Thus, CTMC are sensitive to depletion by compound 48/80,31 whereas
dexamethasone prevents MMC activation. Cytoplasmic granules of CTMC are rich in heparin and
histamine, whereas in MMC the cytoplasmic granules contain the proteoglycan chondroitin-6-suphate,
but low concentrations of histamine [16].
Another difference between MMC and CTMC is the pattern of Arachidonic acid-derived metabolites.
The predominant Arachidonic acid metabolite of CTMC is Prostaglandin D2, whereas MMC generate
predominantly lipoxygenase products such as Leukotriene D4 and Leukotriene E4 [14]. In addition,
the serinproteases of the mast cells have been classified in chymases and tryptases. All the proteases in
the rat are chymases, in MMC rat mast cell protease 2 (RMCP-2), mucosal mast cell protease 5 (MMCP-5),
and Carboxipeptidase, while CTMC produces RMCP-1 [17]. This “plasticity” of multiple aspects of the
mast cell’s results in the development of phenotypically distinct populations of mast cells in different
anatomical sites, as well as in different animal species, is called “mast cell heterogeneity” [18].
Depending on the anatomical site in which the mast cells reside and/or the biological processes in
which they participate allows for greater flexibility and diversity of mast cell responsiveness [19].
The stenosing ligation of the portal vein, also named partial portal vein ligation (Figure 1) [20],
is an experimental model in rodents used to study portal hypertension without associated liver disease.
The portal hypertension obtained this way progresses with a significant increase of mast cells either
in the liver [21] or in the hepato-intestinal axis [10,11,13,22]. That’s why it has been suggested that
these cells would be involved in the exacerbated inflammatory angiogenic response developed in the
abovementioned axis. A great number of mediators from the mast cells have angiogenic functions,
especially histamine, vascular endothelial growth factor (VEGF), and nitric oxide (NO). However,
the mast cells also have the ability to produce lymphangiogenic factors, principally VEGF-A, VEGF-B,
VEGF-C, and VEGF-D [23,24].
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Figure 1. Graphic representation of the porto-systemic collateral circulation in the rat after performing
a partial portal vein ligation. The triple partial portal vein (TPVL) ligation technique has been used
to increase resistance of venous portal flow and subsequently, the portal hypertension degree and
therefore the related splanchnic inflammatory response. Collateral circulation with paraoesophageal
(pe), splenorenal (sr) and pararectal (p) vessels. MLC: mesenteric lymphatic complex; S: spleen.
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Therefore, it should be noted that lymphangiogenesis must be considered among the pathological
consequences of the portal hypertensive splanchnic mastocytosis. In addition, the mast have the
abilities to produce vasodilation and increased permeability of the vascular, blood and lymphatic,
endothelium. These actions are mediated by the production and release by the mast cells of VEGFs and
tryptase, as an activator of protease activated receptors (PAR) and Peroxisome proliferator-activated
receptor-gamma (PPAR-γ), [9,25].
The blood vasodilation, by increasing the blood flow speed, reduces the oxygen uptake by the
intestinal layer cells, while the increase of the blood endothelium permeability causes edema (Figure 2).
So, the intestinal epithelial cells, which normally obtain energy through oxidative phosphorylation,
would be deprived of obtaining oxygen by a dual mechanism. Firstly, this would occur because the
hyperdynamic circulation prevents its blood uptake, and secondly, due to the increased distance to the
blood capillaries cause d by the edematous interstitium.
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Figure 2. The vascular endothelium takes part either in the physiological situation (a), in the splanchnic
inflammatory response related to portal hypertension (b) or in the portal hypertension associated with
chronic liver disease (c). In the physiological situation, a balance between the extent of the arterial
endothelium, venous endothelium, including high endothelial venules, and lymphatic endothelium
exists. This fact is associated with the presence of a specialized hepato-intestinal epithelium. In this
case, the mast cells would make a basic function of maintaining this endothelium-epithelium coupling.
On the contrary, during the progressive development of portal hypertension, the splanchnic mast cell
number increases. Due to their inflammatory activation, they cause progressive interstitial edema.
This impairment coexists with an increase of the leading role of the splanchnic endothelial lymph-venous
at the expense of the arterial endothelium, as well as with a reduction of the specialized functions of
the hepato-intestinal epithelium. Lastly, when portal hypertension is associated with a chronic liver
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disease, the great predominance of the lymph-venous endothelium would correlate with a functional
activation of the mast cells that try to compensate the functional hepatic deficit and preserve the
hepato-intestinal survival mechanisms, i.e., the stem cells. In turn, the splanchnic interstitial edema
would reach its maximal expression. AE: arterial endothelium; E: edema; EC: hepatointestinal epithelial
cells; HEV: high endothelial venule; LE: lymphatic endothelium; MC: mast cell; SC: stem cells; VE:
Venule endothelium.
The splanchnic lymphatic system that is understood more today is the intestinal lymphatic
system since it carries the products derived from food digestion. In fact, its principal function is the
absorption and transport of dietary fat. Spontaneous lacteal contraction, in concert with adjacent
smooth muscles, is essential for drainage of dietary lipids. Thus, the lymphatic pumping activity is
regulated by intraluminal pressure and wall shear stress via differential release of prostaglandins,
NO and histamine [26]. Lymphatic endothelial cell differentiation in vertebrates occurs primarily
from venous endothelial cells, although a mesenchymal origin has also been shown [27]. Lymph
from the gastro-intestinal and lumbar region drains into the cisterna chyli at the posterior end of the
thoracic duct and reaches the circulation in the subclavian vein. In the intestine, lymphatic capillaries,
or lacteals, are located exclusively in intestinal villi, whereas collecting lymphatic vessels are present in
the mesentery (Figure 3) [26].
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In portal hypertension the lymphatic alteration related to the blood vascular impairments is
the basis of the creation of an endothelial blood-lymphatic pathological coupling mediated by the
splanchnic mast cells. In this way, the hypoxic conditions imposed by the blood vascular circulation in
the gastrointestinal tract could be responsible for a pathological lymphatic circulation development.
So, lymphatic capillaries facilitate the interstitial drainage and transport either resident immune cells
or recruited ones. The mediators released by the mast cells, especially heparin and VEGFs, produce an
increase of the lymphatic endothelial permeability as well as lymphangiogenesis [28,29]. It has also
been described that a deficit of the lymphatic vessel contractility is associated with the increase of
lymphatic flow, which strengthens the interstitial edema [26,29,30].
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The microcirculatory impairments in portal hypertension are secondary to the endothelial
metabolic alterations. Although the blood endothelial metabolism has been thoroughly studied in the
angiogenic inflammatory response [27], the lymphatic endothelial metabolism during the inflammatory
response is still the great unknown today. However, it could be supposed that the metabolic alterations
of the lymphatic endothelium in inflammation could be similar to the blood endothelial metabolism,
although with the specificity of the lymphatic endothelium. If so, the metabolic mediation of the mast
cells would integrate the functions of the blood-lymphatic endothelial coupling. The mast cells could
participate by supporting basic substrates for the endothelial metabolism [31]. In particular, through
the support of their precursor amino acids, namely histidine and tryptophan, the corresponding
biogenic amines, histamine, and serotonin respectively, could be synthesized by the mast cells [32].
Histidine is an amino acid that plays a key role in providing methyl donors for DNA and protein
methylation and, therefore, it is a potential producer of epigenetic changes modifying the activation of
certain genes in the endothelium [33,34]. In turn, alanine is a non-essential amino acid that is involved
in the metabolism of tryptophan, which can also be a methyl donor [34,35]. Of note, to the potential
ability of these amino acids to make epigenetic changes, their demonstrated protecting function as part
of the solution for hypothermic preservation of organs in transplantation could be added [36].
Therefore, one of the basic mechanisms that induces gastrointestinal lymphangiogenesis either
in portal hypertension or in liver cirrhosis could not be excluded as epigenetic, even mediated by
mast cells [29]. Hence, the mast cells’ potential use of the biogenic amine precursor amino acids in the
splanchnic inflammation related to portal hypertension suggests that the abovementioned amino acids
serve as a parametabolic link between metabolism and epigenetics [33]. In addition, these amino acids
could be used in the preservation of the splanchnic tissues and organs that are edematous and hypoxic
and, consequently, have an anaerobic metabolism.
3. The Mast Cell and the Lymphatic Gut-Liver Axis
The splanchnic lymphatic pathology related to portal hypertension could be relative to the
inflammatory response mediated by mast cells. In this way, the mast cells are a sensor of the portal
venous pressure increase.
3.1. Mechanotransduction, Liver Disease and Mast Cells
In essence, the mast cells are a physic-chemical sensor because of the mechanotransductor stimulus
received, and therefore a metabolic stimulus is added due to the liver insufficiency. It’s possible
that in the presence of these etiological factors, the mast cells, thanks to their great plasticity [19,37],
simultaneously express different phenotypes. Thus, these two different expressed phenotypes are
a portal hypertensive phenotype and a compensating phenotype of the hepatic functional deficit.
In the case in which portal hypertension may have intrahepatic origin, which is common in chronic
hepatic insufficiency, a severe and progressive metabolic insufficiency is associated. This metabolic
hepatic insufficiency is evaluated through the Child and the Model For End-Stage Liver Disease MELD
scores [38,39]. The Child–Pugh (CP) classification is one of the most common bedside tools utilized in
medicine for gauging the severity of liver disease and estimating prognosis in the patient with cirrhosis.
CP is a composite ordinal score consisting of three laboratory-based biomarkers (serum albumin levels,
serum bilirubin levels, and prothrombin time) and two clinically assessed variables (presence/degree
of ascites and presence/degree of hepatic encephalopathy) [38]. The present version of MELD score
incorporated only 4 objective variables, including total bilirubin, creatinine, international normalized
ratio (INR) and serum sodium level [39]. Therefore, this noxious pathological liver-related factor
would condition the evolution of the lymphatic impairment of portal hypertension.
3.2. Splanchnic Mast Cells and Lymphangiogenesis
We’ve demonstrated the existence of a splanchnic increase in the number, as well as a phenotype
change of the mast cells (CTMC and MMC) in portal hypertension associated with the cholestatic
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hepatic insufficiency that also shows an excessive intestinal lymphangiogenic response (Figures 4
and 5) [40]. In these cholestatic rats, CTMC and MMC showed an increase in the mesenteric lymphatic
complex. MMC increased in the liver and ileum, and both MMC and CTMC increased in the spleen [40].
In a stereological study, by immunolabelling the intestinal lymphatic vessels with LYVE-1, a specific
marker of lymphatic endothelium, we’ve shown that the lymphatic portal hypertensive enteropathy is
characterized by lymphatic length density and microvessel volume fraction increase. These lymphatic
impairments are more marked in the duodenum and ileum. This study demonstrates the existence
of an increased lymphangiogenesis in both sides of the small bowel associated with liver fibrosis
(Figure 5). It also suggests the development of a splanchno-systemic lymphatic collateral circulation in
portal hypertension.
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Figure 4. Connective Tissue mast cells (CTMC) were identified after stained with a 0.5% toluidine blue
solution transversal sections of (A) the lymphatic nodes and in (B) spleen as granulated violet/blue cells)
in cholestatic rats. Mucosal mast cells (MMC), rat mast cell protease 2 (RMCP-II), green immunopositive
cells in (C) the liver and (D) in the ileum of microsurgical cholestatic rats. Immunodetection of RMCP-II,
specific marker of mucosal mast cells (MMC) in the rats, was carried out using a specific rat monoclonal
antibody (1:500; Moredun Animal Health, Edinburgh, UK). The size of the calibration bars throughout
all images was 100 µm.
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(C) I age of an ileum SO-rat: any lymphatic lumen is observed in the villi; (D) ileal image from an
animal with MC showing a relevant enlargement of lymphatic microvessels either in the ucosa (full
stars) as in the submucosa (empty stars). The size of the calibration bars throughout all images was
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spreading of intestinal inflammatory mediators th ough these mesenteric-systemic lymphatic vessels
would have a similar pathogenic result to what their already thoroughly studied sprea ing mediators
have thr ug the porto-syst mic blood bypass. If so, not only micr organisms and their metabolites
(PAMPs) of intestinal rigin, but also other intestinal proinflammatory ediators, like DAMPs,
cytokines and chemoki es, would reach, through the mesenteric-systemic lymphatic bypass, tissues
and organs far off the gastrointestinal tract. This systemic flooding of proinflammatory mediators
secondary to the splanchnic lymphatic disfunction would be worsened by the coexistence of the
immunosuppression in patients with liver diseases.
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3.3. Mast Cells Compensating Chronic Liver Disease
The splanchnic mast cells, behaving as a metabolic sensor in chronic hepatic insufficiency,
would have a modulating behavior of these metabolic alterations [41]. In particular, two functions
that are severely impaired in chronic liver disease, like the detoxing function made by the Kupffer
cells, and the antioxidant function, mediated by the peroxisomes [42], could be partially improved
by the compensating actions of the mast cells [43] (Figure 6). Furthermore, the splanchnic mast
cells could develop metabolic functions that adapt to this new metabolic environment. Therefore,
the ethopathogenic factor most relevant to liver disease that worsens the splanchnic lymphangiogenic
disfunction secondary to portal hypertension would be the hepatic insufficiency [44].
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Figure 6. Schematic representation of the relationship that is established in portal hypertension
associated with cholestatic chronic liver diseases between the mesenteric venous portal and lymphatic
endothelium with the mast cell. The sensor ability of the mast cells to chemical (damage associated
molecular pattern and pathogen associated molecular pattern) and physical (mechanical energy) stimuli
allows it to selectively react by means of its multiple mechanisms to the abovementioned stimulus in
portal hypertension. The mast cells mechanisms of action include degranulation, exosomes/extracellular
vesicles, tunneling nanotubes, extracellular trap formation and mast cells migration to the mesenteric
lymph nodes, where they reach the high endothelial venules (HEVs), and then they would activate the
adaptive immunity. The mast cells through these mechanisms would try to antagonize some of the
impairments that are typical of portal hypertension associated with chronic liver disease. Between
the protecting functions of the mast cells and their ability to antagonize the oxidative stress, the toxic
intestinal substances and the immunologic injury stand out.
The liver diseases, especially if they are chronic with cirrhosis, are characterized by chronic
necroinflammatory and fibrogenetic processes. The key impairments shown in cirrhosis are the
conversion of normal liver architecture into structurally abnormal nodules, dense fibrotic septa,
concomitant parenchymal exhaustion, and collapse of the liver tissue [45]. The unstructured hepatic
parenchyma by fibrosis would obstruct the liver lymphatic drainage; that is, the 25–50% of the lymph
that reaches the thoracic duct. Consequently, this hepatic lymphatic stasis has been involved in the
ascites production [46]. In addition, the liver is the principal metabolic organ of the body. This ability to
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develop the leading role in centralizing the metabolic needs of the body would be impaired in chronic
liver diseases. Actually, in liver cirrhosis, the restructuration of the liver parenchyma by fibrosis blocks
the portal flow and induces the creation of regeneration nodules, which are exclusively vascularized
through the hepatic artery [45]. Therefore, the liver, an organ with double blood vascularization,
is progressively transformed into an organ with simple vascularization that is principally arterial
vascularization. The central metabolic deficit which leads to hepatic insufficiency implies the needed
creation of peripheric compensatory mechanisms in which the mast cells could participate.
A critical function of the liver is the clearance of noxious substances of intestinal origin, like
translocated gut microbiota that arrive via the portal vein in the liver. This function is principally
made by the Kupffer cells that have an extremely effective phagocytic system since they represent
approximately 80% of the phagocytic mononuclear system. Thus, Kupffer cells, the largest tissue
resident macrophage population, are key for the maintenance of liver integrity, as well as the local
initiation and resolution of innate and adaptive immunity [47]. Therefore, they are key modulators
of immune responses at interface organs, such as the skin or gut. This phagocytic function, which
is impaired in liver cirrhosis, could be taken over peripherally by the mast cells, and in particular
by those located in the mesenteric lymph complex. Mast cells have direct phagocytic and indirect
functions since their proteases effectively neutralize endogenous toxins and venoms [48,49]. Thus,
proteases released by activated mast cells detox an array of toxic substances [49]. Moreover, mast cell
proteases achieve an extracellular digestive function. Perhaps this mechanism effectively collaborates
in the support of basic nutrient substrates either to their microenvironment cells or at long distance,
then is transported by the lymphatic system.
In addition, mast cells orchestrate immune cell functions, including essential support for triggering
T-cell expansion by dendritic cells and sometimes even acquisition of dendritic cell antigen-presenting
molecules [48]. In this way, mast cells can prime tissues for adequate inflammatory responses and
cooperate with dendritic cells in T-cell activation. Mast cells also produce antimicrobial peptides like
cathelicidins in response to toll-like receptors mediated by pathogen sensing and interact with innate
immune cells. Thus, the mast cells collaborate with T cells to mount host defenses against viral, bacterial,
fungal, and parasitic infections, e.g. by secreting TNF-α to recruit neutrophils through Toll-like receptor
2-triggered degranulation, or provision of extracellular DNA traps [48,49]. Interstitial intestinal edema
favors lymphatic drainage of noxious substances to the mesenteric lymph nodes. In this way mast
cells recruited by these lymph nodes can act like scavengers of the toxic intestinal products [48,49].
Mast cells’ preformed mediators can trigger vascular responses, in particular vasodilatation and vessel
permeabilization, resulting in tissue edema [49]. The mast cells located in the splanchnic lymphatic axis
can even influence the liver fibrosis evolution through production and systemic release of exosomes [50].
The mast cell exosomes, thanks to their specific content of microRNAs and proteases, could also
induce a systemic anti-inflammatory function as well as reduce the hepatic fibrogenesis. In this sense,
the potential applications of exosomes as biomarkers and therapeutics for liver diseases has been
suggested [51,52].
This lymphatic node detoxing function would be associated with a metabolic burst releasing
reactive oxygen species (ROS) with the subsequent production of oxidative stress. However, the mast
cells have a peroxisome content that performs antioxidant functions, thus reducing the deleterious
effects of ROS. The peroxisomes are small organelles, which are basic for the development of a stress
response [53]. ROS play a leading role among their key functions. In mammalian cells, the oxidative
breakdown of amino acids and fatty acids catalyzed by oxidases results in the transfer of hydrogen.
The substrates sent directly to oxygen thereby generate hydrogen peroxide (H2O2) [54] and then H2O2
that could suffer degradation by catalase into two H2O molecules. This important function is impaired
in the liver diseases, which is why it is considered a key factor in the production of Non-alcoholic
steatohepatitis (NASH) [55,56]. In summary, peroxisome derived activity in mast cells recruited
in the lymphatic mesenteric complex would try to supply or minimize the deficient antioxidant
functions of the diseased liver. Peroxisomal disorders are inherent to the hepatic dysfunction [57].
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However, peroxisome proliferator-activated receptor-beta/delta (PPAR-β/δ) and PPAR-alpha with
multiple anti-inflammatory effects could modulate the mast cell phenotype reducing the levels of
inflammatory cytokines in liver chronic diseases [43,58,59].
The liver is involved in the production of multiple metabolic functions, including lipid metabolism.
Thus, the liver plays a key role in the development of hepatic steatosis and metabolic syndrome [55,56].
This is the reason why the role of the mast cells in the lipid metabolism through their peroxisome ability
for fatty acid beta-oxidation can reduce this liver deficit [59]. The peroxisomes are organelles that can
control metabolic cell functions including lipid metabolism in association with mitochondria [58,60,61].
In mammalian cells, peroxisomes and mitochondria functionally cooperate in the oxidative degradation
of fatty acids by beta-oxidation [62].
In the chronic hepatic insufficiency, the splanchnic inflammation produced by mast cells would
induce hypoxia [63]. Consequently, in chronic liver diseases the metabolic activity is reduced.
Therefore, the oxidative phosphorylation is also inhibited [64], and finally, the energetic support is
limited. This fact would imply the progressive reduction of the specialized epithelial cell number of
the hepato-intestinal axis that consumes great amounts of usable energy (Figure 2). This energy saving
induced by mast cells could also favor the pentose phosphate pathway since, through the formation
of ribose-5-phosphate, the synthesis of nucleotides increases [38]. In this way, the metabolism and
survival of the gastrointestinal and hepatic epithelial stem cells would be prioritized. Consequently, it
could explain how the disappearance of the lobulillar structure is replaced by regeneration nodules [45].
In the intestine, the metabolism of the crypt cells would be prioritized. The stem-cell niche, including
the enteroendocrine cells, i.e., Paneth cells, which are cells-sensory sentinels, can be orchestrators of
mucosal survival [65] when associated with mast cells. In addition, we’ve demonstrated the existence of
goblet cell hyperplasia in portal hypertensive rats with mucus hyperproduction that have a protecting
effect over the intestinal mucosa [66,67].
The coupling lymphatic-mast cell would represent a splanchnic defensive mechanism against
the injury that produces portal hypertension and/or hepatic insufficiency. This coupling is formed
structurally by an anatomical axis in which a poor oxygenated environment predominates (Figure 6).
The intestine maintains a low baseline PO2 level due to high rates of metabolism, countercurrent blood
flow, and the presence of a steep oxygen gradient across the luminal aspect of tissue surface. As a result,
hypoxia exists even in the healthy, unperturbed intestinal mucosa [63]. This homeostatic situation
of intestinal hypoxia aggravates in portal hypertension through the development of a splanchnic
hyperdynamic circulation, and the creation of an anaerobic metabolism, among other factors [67,68].
Therefore, in portal hypertension and/or hepatic insufficiency, the return of the organism to this ancestral
metabolic situation could aim to preserve the hepato-intestinal survival mechanisms (Figure 2).
4. Conclusions
In summary, the reduction of the hepatic metabolism in chronic liver diseases would induce its
central metabolic, detoxing and antioxidant abilities, which are basically mediated by peroxisomes.
As a result, peripherical structures could try to supply the abovementioned functions. In particular,
the mast cell that behaves as a metabolic sensor in the hepatic insufficiency would increase its number
and express its different phenotypes, which would coordinate to compensate the deficiencies caused
by the hepatic insufficiency. Thus, the mast cells with their peroxisomes content would carry out these
partially lost functions in the peripheric organs and tissues, especially in the splanchnic area. At last, it
has been considered that the splanchnic blood vascular stasis not only occurs in liver diseases, but also
in other situations. For instance, in the cases in which the intrabdominal pressure increases, like in
obesity or a sedentary lifestyle, the splanchnic, venous stasis would produce a chronic low-grade
gut-related inflammatory response by mechanotransduction. If so, a mast cell compensatory reaction
takes place, which is associated with a splanchnic circulatory switch with increased development of a
venous-lymphatic circulation at the expense of the arterial circulation.
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